Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma
批准号:
10427946
负责人:
Amit Singal
金额:
$9.36万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-04-03 至 2024-11-30
关键词:
AffectAgeBiologicalBiological FactorsBlack PopulationsCancer EtiologyCenters for Population HealthCessation of lifeClinicClinicalComputerized Medical RecordCubanDataData ReportingDatabasesDiagnosisDistalEpidemiologyEthnic OriginGrantGuidelinesHealthHealth Disparities ResearchHealth ServicesHepatologyHispanicHospitalsIncomeIndividualInequalityInterventionKnowledgeLiver DysfunctionMalignant NeoplasmsMeasuresMexicanMinority GroupsModelingMulticenter StudiesNeighborhoodsNewly DiagnosedNot Hispanic or LatinoOutcomePathway interactionsPatientsPersonsPopulationPopulation HeterogeneityPrimary carcinoma of the liver cellsPrognosisProviderPublic HealthRaceRegistriesReportingSerumSiteSocial ConditionsSocial PoliciesSocial supportSocioeconomic StatusStage at DiagnosisStatistical MethodsSubgroupSystemTimeTranslational ResearchTumor BiologyTumor stageUniversitiesbasebiobankblack patientclinical databasecohortdemographicsdisadvantaged populationdisparity reductionethnic minorityhealth care service utilizationhealth disparityhealth disparity populationshealth literacyhealth outcome disparityimplicit biasimprovedinterestintersectionalitylow socioeconomic statusmortalitymultidisciplinarymultilevel analysisprognosticprospectiveracial and ethnicracial and ethnic disparitiesracial determinantresponsesegregationsocialsocial relationshipssocioeconomic disadvantagesocioeconomic disparitysocioeconomicssurvival disparitytumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Hepatocellular carcinoma (HCC) is the fastest growing cause of cancer-related death in the U.S. HCC
disproportionally affects racial/ethnic minority and socioeconomically disadvantaged populations, with higher
age-adjusted mortality observed in non-Hispanic blacks and Hispanic whites than non-Hispanic whites. To
evaluate these disparities, we will use an adapted Warnecke/Centers for Population Health and Health
Disparities ecological multi-level model attributing disparate health outcomes to biological-environmental
interactions between and across distal (population social conditions and policies), intermediate (social and
physical contexts including social relationships), and proximal (individual demographics and biological
responses) determinants. Applying this model to HCC disparities will facilitate identification of key drivers of
disparities in prognosis, which is the first necessary step to develop intervention strategies aimed at improving
survival and reducing disparities following HCC diagnosis. Specifically, our proposal will characterize the
contribution of proximal, intermediate, and distal determinants to disparities in 3 known measures of HCC
prognosis: a) tumor stage at diagnosis, b) receipt of timely and guideline-concordant HCC treatment, and c)
overall survival. Leveraging existing clinical databases and a biorepository of stored serum, we will conduct a
multi-center study using electronic medical record-derived, patient-reported, provider-reported, and serum-
based biological factors in a cohort of ~5000 patients newly diagnosed with HCC over a 13-year period to:
Aim 1: Characterize the contribution of proximal, intermediate, and distal determinants of
racial/ethnic and socioeconomic disparities in HCC tumor stage at diagnosis
Aim 2: Determine racial/ethnic and socioeconomic disparities in receipt of timely and guideline-
concordant HCC treatment including proximal, intermediate, and distal determinants
Aim 3: Identify proximal, intermediate, and distal determinants of racial/ethnic and socioeconomic
disparities in overall survival following HCC diagnosis
Overall, we will identify factors across and within multiple levels associated with disparities in HCC prognosis
between non-Hispanic white, Hispanic white, and non-Hispanic black patients as well as low versus high SES
class in a large, racial/ethnically and socioeconomically diverse diverse cohort of ~5000 HCC patients. Our
study will provide an understanding of why HCC prognosis disparities exist and at what level interventions
should be implemented to reduce disparities improving overall survival.
期刊论文(40)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma.
寻求针对肝细胞癌的免疫检查点抑制剂的精准肿瘤学。
DOI:
10.1016/j.jhep.2021.11.021
发表时间:
2022
期刊:
Journal of hepatology
影响因子:
25.7
作者:
[Cabibbo,Giuseppe, Singal,AmitG]
通讯作者:
Singal,AmitG
DOI:
10.1002/hep4.1863
发表时间:
2022-05
期刊:
HEPATOLOGY COMMUNICATIONS
影响因子:
5.1
作者:
[Wagle, Nikita Sandeep, Park, Sulki, Washburn, David, Ohsfeldt, Robert L., Rich, Nicole E., Singal, Amit G., Kum, Hye-Chung]
通讯作者:
Kum, Hye-Chung
DOI:
10.1097/hc9.0000000000000162
发表时间:
2023-06-01
期刊:
Hepatology communications
影响因子:
5.1
作者:
[]
通讯作者:
DOI:
10.1002/hep4.1795
发表时间:
2022-01
期刊:
Hepatology communications
影响因子:
5.1
作者:
[Govalan R, Luu M, Lauzon M, Kosari K, Ahn JC, Rich NE, Nissen N, Roberts LR, Singal AG, Yang JD]
通讯作者:
Yang JD
DOI:
10.1007/s10620-019-05890-2
发表时间:
2020-06
期刊:
Digestive diseases and sciences
影响因子:
3.1
作者:
[Scaglione S, Adams W, Caines A, Devlin P, Mittal S, Singal AG, Parikh ND]
通讯作者:
Parikh ND
共 25 条
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States
-
批准号:10477966
-
项目类别:
-
资助金额:$71.89万
-
财政年份:2018
-
负责人:Amit Singal
-
依托单位:
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States
-
批准号:9980310
-
项目类别:
-
资助金额:$69.3万
-
财政年份:2018
-
负责人:Amit Singal
-
依托单位:
Precision Risk Stratification and Screening for HCC among Patients with Cirrhosis in the United States
-
批准号:10225536
-
项目类别:
-
资助金额:$70.17万
-
财政年份:2018
-
负责人:Amit Singal
-
依托单位:
Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis
-
批准号:10365950
-
项目类别:
-
资助金额:$39.91万
-
财政年份:2018
-
负责人:Amit Singal
-
依托单位:
Precision Screening for Hepatocellular Carcinoma in Patients with Cirrhosis
-
批准号:10543119
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2018
-
负责人:Amit Singal
-
依托单位:
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma
-
批准号:10058774
-
项目类别:
-
资助金额:$92.28万
-
财政年份:2018
-
负责人:Amit Singal
-
依托单位:
Multilevel factors for racial/ethnic and socioeconomic disparities in prognosis of hepatocellular carcinoma
-
批准号:10308039
-
项目类别:
-
资助金额:$89.87万
-
财政年份:2018
-
负责人:Amit Singal
-
依托单位:
Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis
-
批准号:10018464
-
项目类别:
-
资助金额:$60.99万
-
财政年份:2017
-
负责人:Amit Singal
-
依托单位:
Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis
-
批准号:9753994
-
项目类别:
-
资助金额:$29.74万
-
财政年份:2017
-
负责人:Amit Singal
-
依托单位:
Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis
-
批准号:10237359
-
项目类别:
-
资助金额:$59.94万
-
财政年份:2017
-
负责人:Amit Singal
-
依托单位:
Harms of Hepatocellular Carcinoma Screening in Patients with Cirrhosis
-
批准号:10447796
-
项目类别:
-
资助金额:$37.68万
-
财政年份:2017
-
负责人:Amit Singal
-
依托单位:
Population Science and Cancer Control Program
-
批准号:10170616
-
项目类别:
-
资助金额:$5.28万
-
财政年份:2010
-
负责人:Amit Singal
-
依托单位:
Population Science and Cancer Control Program
-
批准号:10693215
-
项目类别:
-
资助金额:$5.28万
-
财政年份:2010
-
负责人:Amit Singal
-
依托单位:
Population Science and Cancer Control Program
-
批准号:10477975
-
项目类别:
-
资助金额:$5.28万
-
财政年份:2010
-
负责人:Amit Singal
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: